AlphaYou
Overview
Smart money at a glance
Filings to Oct 2, 2026Net selling: insiders sold $7.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$7.1M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Oct 2- Open
- $33.17
- 52-wk high
- $52.93
- High
- $34.05
- 52-wk low
- $23.75
- Low
- $32.62
- Prev close
- $33.02
- Mkt cap
- $1.61B
- Volume
- 582.0K
- Beta
- 1.03
- P/S
- 80.6x
- P/B
- 3.9x
- Profit margin
- +0.0%
- Op margin
- -768.0%
- ROE
- -40.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about RAPP filings
Are insiders buying or selling Rapport Therapeutics, Inc. Common Stock (RAPP) stock?
Net selling: insiders sold $7.1M and bought $0 of RAPP stock on the open market in the 90 days to Oct 2, 2026, according to SEC Form 4 filings. $7.1M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Ceesay, Abraham (Chief Executive Officer), who sold $4.3M. The latest filing was on Oct 1, 2026.
Which members of Congress have traded RAPP recently?
None. No member of Congress disclosed a RAPP trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this RAPP smart-money data?
This summary uses filings available on Oct 2, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What insiders are doing
How top traders are positioned
No tracked top-trader positions in RAPP right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 28.0% below what analysts expected.
Earnings per share
-$0.93 expected
Reports Nov 5, 2026, in 34 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $20.0M | $0 |
| Cost of what it sold | $256.0K | $265.0K | $227.0K | — |
| Gross profit | -$256.0K | -$265.0K | $20.0M | — |
| What it spent | ||||
| Research and development | $22.3M | $30.3M | $32.7M | $51.4M |
| Sales and admin | $7.7M | $8.3M | $11.5M | $9.4M |
| Total operating expenses | $30.0M | $38.5M | $44.2M | $60.8M |
| What was left | ||||
| Operating profit | -$30.0M | -$38.5M | -$24.2M | -$60.8M |
| Profit before tax | -$26.9M | -$33.8M | -$19.9M | -$56.6M |
| Net profit | -$26.9M | -$33.8M | -$19.9M | -$56.6M |
| EBITDA | -$29.7M | -$38.2M | -$24.0M | -$56.2M |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace